<section class="max-w-7xl mx-auto px-4 pb-4 md:px-8 mt-10">
  <p>
    <strong>Referencias:</strong>
    <strong>1.</strong> Oelkers W. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone. Eur J Contracept Reprod Health Care. 2002;7 Suppl 3:19-26;42-3.
    <strong>2.</strong> Apter D, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contrac Rep Health Care 2003; 8: 37-51.
    <strong>3.</strong> Fenton C, et al. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs 2007; 67:1749-65.
    <strong>4.</strong> Pérez E. Ethinylestradiol/Dienogest in Oral Contraception 2010. Drugs. 2010;70 (6):681-9.
    <strong>5.</strong> Palacio-Cardona J, Caicedo Borrero DM. Clinical behavior of a cohort of adult women with facial acne treated with combined oral contraceptive: ethinylestradiol 20 μg/dienogest 2 mg. Inter J Women Health. 2017;9:835-42.
    <strong>6.</strong> Abbott Laboratories. Bellaface® 20. Monografía de producto.
  </p>
</section>